Drugs / YH14755
last change Jul 2017 re-read 2 minutes ago

YH14755

Developed for
hyperlipidemia · type 2 diabetes mellitus
Investigated by
Yuhan Corporation

Trials 2 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02125227 Apr → Sep 2014 Yuhan Corporation Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02586129 Nov 2015 → Jul 2017 hyperlipidemia, type 2 diabetes mellitus Yuhan Corporation Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as YH14755 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02586129
1

NCT02125227

Route Oral “PO, Once Daily, 16 weeks” NCT02586129